102 related articles for article (PubMed ID: 16808005)
1. Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum.
Subehan ; Usia T; Kadota S; Tezuka Y
Planta Med; 2006 May; 72(6):527-32. PubMed ID: 16808005
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.
Heydari A; Yeo KR; Lennard MS; Ellis SW; Tucker GT; Rostami-Hodjegan A
Drug Metab Dispos; 2004 Nov; 32(11):1213-7. PubMed ID: 15328252
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-based CYP2D6 inactivation by acridone alkaloids of Indonesian medicinal plant Lunasia amara.
Takahashi N; Subehan ; Kadota S; Tezuka Y
Fitoterapia; 2012 Jun; 83(4):774-9. PubMed ID: 22465502
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of the cytochrome P450 isoform by hyperoside and its potent inhibition of CYP2D6.
Song M; Hong M; Lee MY; Jee JG; Lee YM; Bae JS; Jeong TC; Lee S
Food Chem Toxicol; 2013 Sep; 59():549-53. PubMed ID: 23835282
[TBL] [Abstract][Full Text] [Related]
5. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6.
Jones BC; Hyland R; Ackland M; Tyman CA; Smith DA
Drug Metab Dispos; 1998 Sep; 26(9):875-82. PubMed ID: 9733666
[TBL] [Abstract][Full Text] [Related]
6. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
[TBL] [Abstract][Full Text] [Related]
7. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
Van LM; Heydari A; Yang J; Hargreaves J; Rowland-Yeo K; Lennard MS; Tucker GT; Rostami-Hodjegan A
J Psychopharmacol; 2006 Nov; 20(6):834-41. PubMed ID: 16478752
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]- 4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction.
Hutzler JM; Steenwyk RC; Smith EB; Walker GS; Wienkers LC
Chem Res Toxicol; 2004 Feb; 17(2):174-84. PubMed ID: 14967005
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes.
Cho DY; Bae SH; Lee JK; Kim YW; Kim BT; Bae SK
Drug Metab Dispos; 2014 Jan; 42(1):33-9. PubMed ID: 24167220
[TBL] [Abstract][Full Text] [Related]
10. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6.
Madeira M; Levine M; Chang TK; Mirfazaelian A; Bellward GD
Drug Metab Dispos; 2004 Apr; 32(4):460-7. PubMed ID: 16680870
[TBL] [Abstract][Full Text] [Related]
11. Tryptamine: a possible endogenous substrate for CYP2D6.
Martínez C; Agúndez JA; Gervasini G; Martín R; Benítez J
Pharmacogenetics; 1997 Apr; 7(2):85-93. PubMed ID: 9170145
[TBL] [Abstract][Full Text] [Related]
12. ACAT inhibition of alkamides identified in the fruits of Piper nigrum.
Rho MC; Lee SW; Park HR; Choi JH; Kang JY; Kim K; Lee HS; Kim YK
Phytochemistry; 2007 Mar; 68(6):899-903. PubMed ID: 17188313
[TBL] [Abstract][Full Text] [Related]
13. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
Bertelsen KM; Venkatakrishnan K; Von Moltke LL; Obach RS; Greenblatt DJ
Drug Metab Dispos; 2003 Mar; 31(3):289-93. PubMed ID: 12584155
[TBL] [Abstract][Full Text] [Related]
14. Effect of sodium ozagrel on the activity of rat CYP2D6.
Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D
Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725
[TBL] [Abstract][Full Text] [Related]
15. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents.
Etheridge AS; Black SR; Patel PR; So J; Mathews JM
Planta Med; 2007 Jul; 73(8):731-41. PubMed ID: 17611934
[TBL] [Abstract][Full Text] [Related]
16. NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine.
Zhao SX; Dalvie DK; Kelly JM; Soglia JR; Frederick KS; Smith EB; Obach RS; Kalgutkar AS
Chem Res Toxicol; 2007 Nov; 20(11):1649-57. PubMed ID: 17907785
[TBL] [Abstract][Full Text] [Related]
17. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes.
Foroozesh M; Primrose G; Guo Z; Bell LC; Alworth WL; Guengerich FP
Chem Res Toxicol; 1997 Jan; 10(1):91-102. PubMed ID: 9074808
[TBL] [Abstract][Full Text] [Related]
18. Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine.
Palamanda JR; Casciano CN; Norton LA; Clement RP; Favreau LV; Lin C; Nomeir AA
Drug Metab Dispos; 2001 Jun; 29(6):863-7. PubMed ID: 11353755
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human P450 enzymes by natural extracts used in traditional medicine.
Rodeiro I; Donato MT; Jimenez N; Garrido G; Molina-Torres J; Menendez R; Castell JV; Gómez-Lechón MJ
Phytother Res; 2009 Feb; 23(2):279-82. PubMed ID: 18844254
[TBL] [Abstract][Full Text] [Related]
20. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components.
Chatterjee P; Franklin MR
Drug Metab Dispos; 2003 Nov; 31(11):1391-7. PubMed ID: 14570772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
